DUBLIN – Bergenbio ASA raised NOK219.9 million (US$23.9 million) in a private placement priced at NOK18 per share. The fresh injection of cash will enable the Bergen, Norway-based firm to expand its broad development program for lead drug candidate bemcentinib (BGB-324), a first-in-class Axl inhibitor, which is currently in phase II development in acute myeloid leukemia (AML), non-small-cell lung cancer (NSCLC), triple-negative breast cancer and melanoma.

Biopharmas raising money in public or private financings, including: Albireo, Alector, Applied Genetic Technologies, Catabasis, DBV, Hemogenyx, Iox, Lyra, Portage, Seelos, Spero, Vizgen.

Timber Pharmaceuticals LLC, a startup created by New Jersey-based investment and operating firm Tardimed Sciences LLC, said it's poised to make a fresh leap into the public market this year with plans to take over Biopharmx Corp.'s NYSE listing in a new reverse merger deal.

Biopharmas raising money in public or private financings, including Alector, Annovis, Atyr, Biohaven, Cocrystal, Denali, Idbydna, Salarius, Trillium

Biopharmas raising money in public or private financings, including: Applied Therapeutics, Autolus, Concert, Denali, Immunogen, Intelgenx, Vascular Therapies, Vaxil, Xenon

Biopharmas raising money in public or private financings, including: Adaptimmune, Arix, Beam, Quench Bio, Nanoviricides, Vaccibody, Zymeworks

Biopharmas raising money in public or private financings, including: Applied Therapeutics

Biopharmas raising money in public or private financings, including: Autolus, Blueprint Medicines, Chi-Med, Genprex, Karuna, Immunogen, Puretech Health, Seneca, Tetraphase, Trillium, Vitro Diagnostics, Xenon, Zymeworks